Serum Life Science Europe

Serum Life Science Europe

Marburg, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Serum Life Science Europe GmbH is a specialized consultancy and service provider for biopharmaceutical development, with deep expertise in vaccines and biologics. Originally founded as Vakzine Projekt Management GmbH with German federal support, the company now operates as an independent entity majority-owned by the Serum Institute of India (SIIPL). SLS Europe generates revenue through client services while advancing its own pipeline of three main clinical-stage assets, including a novel tuberculosis vaccine candidate.

Infectious DiseaseOncologyImmunology

Technology Platform

Integrated consultancy and project management service platform for biopharmaceutical development; expertise in recombinant live-attenuated vaccine engineering (for proprietary assets).

Opportunities

The late-stage TB vaccine candidate VPM1002 addresses a massive global health need with multi-billion dollar potential, supported by WHO priority.
The growing biotech sector in Europe and increasing complexity of drug development create sustained demand for high-quality, specialized consultancy and clinical trial sponsorship services.

Risk Factors

The company's proprietary value is heavily dependent on the clinical success of out-licensed assets, over which it has limited operational control.
The competitive landscape for biopharma consulting services is intense, requiring constant differentiation.
Strategic direction could be influenced by its majority owner, SIIPL.

Competitive Landscape

In consultancy services, SLS Europe competes with global CROs (IQVIA, PPD) and niche regulatory consultancies. For its TB vaccine, it competes with other late-stage candidates from GSK (MTBVAC) and the Immune Response BioPharma/Aeras collaboration. In bladder cancer immunotherapy, it faces competition from established instillations and newer gene therapies.